MARKET

EVOK

EVOK

Evoke Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.580
+0.190
+13.67%
After Hours: 1.500 -0.08 -5.06% 18:51 05/07 EDT
OPEN
1.400
PREV CLOSE
1.390
HIGH
1.590
LOW
1.400
VOLUME
283.47K
TURNOVER
--
52 WEEK HIGH
6.06
52 WEEK LOW
1.280
MARKET CAP
51.15M
P/E (TTM)
-3.0420
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 2d ago
8-K: Evoke Pharma Inc
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
Evoke Pharma to Report First Quarter 2021 Financial Results on May 12, 2021
Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its first quarter 2021 financial results on Wednesday, Ma...
GlobeNewswire · 3d ago
Clover Health Investments, Harrow Health leads healthcare gainers; Editas Medicine, Timber Pharmaceuticals among major losers
Gainers: Clover Health Investments (CLOV) +20%, Harrow Health (HROW) +12%, Brooklyn ImmunoTherapeutics (BTX) +8%, Evoke Pharma (EVOK) +8%, F-star Therapeutics (FSTX) +7%.Losers: Editas Medicine (EDIT) -15%, Timber Pharmaceuticals (TMBR) -14%, Trevena (TRVN...
Seekingalpha · 04/16 14:58
Evoke Pharma gets notice of allowance from united states patent and trademark office
Evoke Pharma (EVOK) announces that the United States Patent and Trademark Office ((USPTO)) issued a Notice of Allowance  for U.S. Application No. 16/181,841 for Gimoti (metoclopramide) nasal spray.The patent will cover methods of
Seekingalpha · 04/06 13:03
BRIEF-Evoke Pharma Receives Notice Of Allowance From U.S. Patent And Trademark Office
reuters.com · 04/06 12:40
Mid-Afternoon Market Update: Dow Surges Over 200 Points; Prometheus Biosciences Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.68% to 32,705.07 while the NASDAQ fell 1.04% to 13,259.09. The S&P also fell, dropping 0.17% to 3,932.46.
Benzinga · 03/12 19:42
MVIS, RIDE, XXII and MRKR among midday movers
Gainers: NLS Pharmaceutics (NLSP) +87%.Entera Bio (ENTX) +72%.Seelos Therapeutics (SEEL) +69%.Ebang International (EBON) +43%.Perpetua Resources (PPTA) +27%.AMREP (AXR) +21%.22nd Century (XXII) +19%.Aemetis (AMTX) +18%.LendingClub (LC) +18%.MicroVision (MV...
Seekingalpha · 03/12 17:43
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EVOK. Analyze the recent business situations of Evoke Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EVOK stock price target is 9.50 with a high estimate of 10.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 38
Institutional Holdings: 3.08M
% Owned: 9.51%
Shares Outstanding: 32.37M
TypeInstitutionsShares
Increased
10
703.32K
New
7
94.85K
Decreased
5
20.71K
Sold Out
3
24.55K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.86%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Co-Founder/Director
Cam Garner
Chief Executive Officer/Founder/Director
David Gonyer
Executive Vice President/Treasurer/Secretary
Matthew D'Onofrio
Other
Marilyn Carlson
Director
Todd Brady
Director
Ann Rhoads
Director
Ken Widder
Director
Kenneth Widder
No Data
About EVOK
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Webull offers kinds of Evoke Pharma Inc stock information, including NASDAQ:EVOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVOK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVOK stock methods without spending real money on the virtual paper trading platform.